Targeting ‘Undruggable’ Targets: Pioneering Novel Applications of Heterobifunctional Degraders – An Update

• Outlining the Astellas’ approach to targeted protein degradation
• Updating on the progress of Setidegrasib (ASP3082) and next-generation degrader candidates in the pipeline
• Introducing Astellas’ integrated R&D model combining in-house discovery, translational science, and external innovation to accelerate progress

Speakers:

David Barrett

Head of Engineered Small Molecules

Astellas